These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 12700446

  • 1. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.
    Mallon PW, Miller J, Cooper DA, Carr A.
    AIDS; 2003 May 02; 17(7):971-9. PubMed ID: 12700446
    [Abstract] [Full Text] [Related]

  • 2. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.
    Clin Infect Dis; 2005 Dec 01; 41(11):1662-70. PubMed ID: 16267741
    [Abstract] [Full Text] [Related]

  • 3. Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults.
    Egaña-Gorroño L, Martínez E, Pérez I, Escribà T, Domingo P, Gatell JM, Arnedo M.
    J Antimicrob Chemother; 2014 Nov 01; 69(11):3076-84. PubMed ID: 25185137
    [Abstract] [Full Text] [Related]

  • 4. Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy.
    Calmy A, Carey D, Mallon PW, Wand H, Law M, Cooper DA, Carr A, INITIO Trial International Co-ordinating Committee, HAMA study coordination team.
    HIV Med; 2008 Feb 01; 9(2):101-10. PubMed ID: 18257772
    [Abstract] [Full Text] [Related]

  • 5. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J.
    HIV Med; 2006 Jan 01; 7(1):38-45. PubMed ID: 16313291
    [Abstract] [Full Text] [Related]

  • 6. Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study).
    Martin A, Smith D, Carr A, Hoy J, Chuah J, Mallal S, Law M, Clements M, Cooper DA, PIILR Study Group.
    HIV Clin Trials; 2004 Jan 01; 5(4):192-200. PubMed ID: 15472793
    [Abstract] [Full Text] [Related]

  • 7. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A, First Pediatric Switch Study.
    Pediatrics; 2003 Mar 01; 111(3):e275-81. PubMed ID: 12612284
    [Abstract] [Full Text] [Related]

  • 8. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children.
    Viganò A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, Vanzulli A, Manzoni P, Brambilla P.
    J Acquir Immune Defic Syndr; 2003 Apr 15; 32(5):482-9. PubMed ID: 12679698
    [Abstract] [Full Text] [Related]

  • 9. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
    Autar RS, Boyd MA, Wit FW, Ruxrungthams K, Sankote J, Lange J, Cooper DA, Phanuphak P, Burger DM, Reiss P.
    Antivir Ther; 2007 Apr 15; 12(8):1265-71. PubMed ID: 18240866
    [Abstract] [Full Text] [Related]

  • 10. Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.
    Ribera E, Larrousse M, Curran A, Negredo E, Clotet B, Estrada V, Sanz J, Berenguer J, Rubio R, Pulido F, Ferrer P, Alvarez ML, Arterburn S, Martínez E.
    HIV Med; 2013 Jul 15; 14(6):327-36. PubMed ID: 23298339
    [Abstract] [Full Text] [Related]

  • 11. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J, Rickenbach M, Weber R, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC.
    Antivir Ther; 2005 Jul 15; 10(1):73-81. PubMed ID: 15751765
    [Abstract] [Full Text] [Related]

  • 12. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women.
    McDermott AY, Shevitz A, Knox T, Roubenoff R, Kehayias J, Gorbach S.
    Am J Clin Nutr; 2001 Nov 15; 74(5):679-86. PubMed ID: 11684538
    [Abstract] [Full Text] [Related]

  • 13. Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.
    Carr A, Ritzhaupt A, Zhang W, Zajdenverg R, Workman C, Gatell JM, Cahn P, Chaves R.
    AIDS; 2008 Nov 12; 22(17):2313-21. PubMed ID: 18981770
    [Abstract] [Full Text] [Related]

  • 14. Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study.
    Bonnet E, Ruidavets JB, Genoux A, Mabile L, Busato F, Obadia M, Prévoteau F, Marchou B, Massip P, Marion-Latard F, Delpierre C, Bernard J, Perret B.
    BMC Infect Dis; 2013 Jun 28; 13():293. PubMed ID: 23809140
    [Abstract] [Full Text] [Related]

  • 15. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.
    Pediatrics; 2002 Feb 28; 109(2):E25. PubMed ID: 11826235
    [Abstract] [Full Text] [Related]

  • 16. Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infected patients receiving highly active antiretroviral therapy.
    Asensi V, Martín-Roces E, Carton JA, Collazos J, Maradona JA, Alonso A, Medina M, Aburto JM, Martínez E, Rojo C, Bustillo E, Fernández C, Arribas JM.
    Clin Infect Dis; 2004 Jul 15; 39(2):240-7. PubMed ID: 15307034
    [Abstract] [Full Text] [Related]

  • 17. [To evaluate the changes in body composition in male human immunodeficiency virus-related lipodystrophy after different treatment regimens by dual-energy X-ray absorptiometry].
    Zhou X, Yu W, Li T, Guo F, Lin Q, Shao H, Tian J, Xu Y, Sun P.
    Zhonghua Nei Ke Za Zhi; 2014 Aug 15; 53(8):622-5. PubMed ID: 25376824
    [Abstract] [Full Text] [Related]

  • 18. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz.
    Viganò A, Brambilla P, Cafarelli L, Giacomet V, Borgonovo S, Zamproni I, Zuccotti G, Mora S.
    Antivir Ther; 2007 Aug 15; 12(3):297-302. PubMed ID: 17591019
    [Abstract] [Full Text] [Related]

  • 19. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
    Sutinen J, Walker UA, Sevastianova K, Klinker H, Häkkinen AM, Ristola M, Yki-Järvinen H.
    Antivir Ther; 2007 Aug 15; 12(1):97-105. PubMed ID: 17503753
    [Abstract] [Full Text] [Related]

  • 20. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy.
    Brambilla P, Bricalli D, Sala N, Renzetti F, Manzoni P, Vanzulli A, Chiumello G, di Natale B, Viganò A.
    AIDS; 2001 Dec 07; 15(18):2415-22. PubMed ID: 11740192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.